Clinical Trial Detail

NCT ID NCT03326921
Title HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

acute lymphoblastic leukemia

mixed phenotype acute leukemia

juvenile myelomonocytic leukemia

chronic myeloid leukemia

acute myeloid leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Fludarabine

HA-1 TCR T cells

Age Groups: senior child

No variant requirements are available.